Ireland
--:--IST
Latest
Clinical Trials in France / NCT06079294
Recruiting Not applicable

Impact of Confirmed Autoimmune Encephalitis on Brain Glucose Metabolism

NCT06079294 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2024-05-31
Last updated
2025-08-22

Condition(s) studied

Autoimmune Encephalitis

Investigational drug(s) / intervention(s)

FDG PET

FDG PET: Brain FDG PET performed 3 months after treatment initiation

Study summary

Prospective cohort study evaluating FDG PET in 56 patients with confirmed autoimmune encephalitis - based on 2016 Graus criteria, and 2021 paraneoplastic neurological syndromes criteria - at the acute phase, before immunomodulating treatment, or within 10 days of treatment initiation.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Age ≥ 18 years old * Newly diagnosed autoimmune encephalitis based on at least 1 of the 3 following criteria : 1. " Definite limbic autoimmune encephalitis " according to 2016 Graus et al. criteria 2. " Possible autoimmune encephalitis " according to 2016 Graus et al. criteria AND typical autoantibody detected in serum or CSF 3. " Probable or certain paraneoplastic neurological syndrome " according to Graus et al. 2021 criteria (excluding peripheral neurological syndromes) * Less than 6 months since first neurological symptoms imputable to autoimmune encephalitis * Affiliated or entitled to a social security system (except AME) * Obtaining free, written and informed consent (patient or legal representative or the close relative) Exclusion criteria * History of brain tumor, head trauma, infarction or cerebral hematoma likely to result in altered cerebral carbohydrate metabolism on PET * Patients who hae been on immunotherapy (corticosteroid bolus, IVIg, plasma exchange, endoxan, rituximab or other immunotherapy) fr more than 10 days * Pregnant or breast-feeding woman * Ventilated intubated patient * Absolute contraindication to MRI (Pacemaker, cochlear implant, etc.) * Presence of cognitive disorders incompatible with goog cooperation with the PET scan * Algic or agitated patient unable to remain immobile in supine position for 30 minutes * Deprived of liberty or under a protective measure (guardianship or curatorship) * Patient taking part in other interventional research involving radiopharmaceutical injections

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Hospital Pitie Salpetriere Paris France Recruiting

More Assistance Publique - Hôpitaux de Paris trials in France

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06079294 on ClinicalTrials.gov ↗ ← All trials in France